Structural glycobiology of antibody recognition in xenotransplantation and cancer immunotherapy

Anticarbohydrate Antibodies: From Molecular Basis to Clinical Application

Volumn , Issue , 2014, Pages 203-228

  Agostino, Mark ^a   Farrugia, William ^b   Sandrin, Mauro S ^c   Scott, Andrew M ^d   Yuriev, Elizabeth ^a   Ramsland, Paul A ^a,b,c  

^a MONASH UNIVERSITY   (Australia)

^b BURNET INSTITUTE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84859989941     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-7091-0870-3_9     Document Type: Chapter

References (100)

1. Agostino M, Jene C, Boyle T, Ramsland PA, Yuriev E (2009a) Molecular docking of carbohydrate ligands to antibodies: structural validation against crystal structures. J Chem Inf Model 49: 2749-2760
2. Agostino M, Sandrin MS, Thompson PE, Yuriev E, Ramsland PA (2009b) In silico analysis of antibody-carbohydrate interactions and its application to xenoreactive antibodies. Mol Immunol 47: 233-246
3. Agostino M, Sandrin MS, Thompson PE, Yuriev E, Ramsland PA. (2010). Identification of preferred carbohydrate binding modes in xenoreactive antibodies by combining conformational filters and binding site maps. Glycobiology 20: 724-735
4. Ajani JA, Kelsen DP, Haller D, Hargraves K, Healey D. (2000). A multi-institutional phase II study of BMS-182248-01 (BR96-doxorubicin conjugate) administered every 21 days in patients with advanced gastric adenocarcinoma. Cancer J 6: 78-81
5. Basnet NB, Ide K, Tahara H, Tanaka Y, Ohdan H. (2010). Deficiency of N-glycolylneuraminic acid and Gala1-3Galb1-4GlcNAc epitopes in xenogeneic cells attenuates cytotoxicity of human natural antibodies. Xenotransplantation 17: 440-448
6. Brooks CL, Schietinger A, Borisova SN, Kufer P, Okon M, Hirama T, MacKenzie CR, Wang LX, Schreiber H, Evans SV. (2010). Antibody recognition of a unique tumor-specific glycopeptide antigen. Proc Natl Acad Sci USA 107: 10056-10061
7. Byrne GW, Stalboerger PG, Du Z, Davis TR, McGregor CG. (2011). Identification of new carbohydrate and membrane protein antigens in cardiac xenotransplantation. Transplantation. doi: 10.1097/TP.0b013e318203c27d
8. Cairns T, Lee J, Goldberg LC, Hakim N, Cook T, Rydberg L, Samuelsson B, Taube D. (1996). Thomsen-Friedenreich and PK antigens in pig-to-human xenotransplantation. Transplant Proc 28: 795-796
9. Calarese DA, Scanlan CN, Zwick MB, Deechongkit S, Mimura Y, Kunert R, Zhu P, Wormald MR, Stanfield RL, Roux KH, Kelly JW, Rudd PM, Dwek RA, Katinger H, Burton DR, Wilson IA. (2003). Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300: 2065-2071
10. Carr A, Mullet A, Mazorra Z, Vázquez AM, Alfonso M, Mesa C, Rengifo E, Pérez R, Fernández LE. (2000). A mouse IgG1 monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors. Hybridoma 19: 241-247
11. Cazet A, Julien S, Bobowski M, Burchell J, Delannoy P. (2010). Tumour-associated carbohydrate antigens in breast cancer. Breast Cancer Res 12: 204
12. Chang WW, Lee CH, Lee P, Lin J, Hsu CW, Hung JT, Lin JJ, Yu JC, Shao LE, Yu J, Wong CH, Yu AL. (2008). Expression of Globo H and SSEA3 in breast cancer stem cells and the involvement of fucosyl transferases 1 and 2 in Globo H synthesis. Proc Natl Acad Sci USA 105: 11667-11672
13. Chou HH, Takematsu H, Diaz S, Iber J, Nickerson E, Wright KL, Muchmore EA, Nelson DL, Warren ST, Varki A. (1998). A mutation in human CMP-sialic acid hydroxylase occurred after the Homo-Pan divergence. Proc Natl Acad Sci USA 95: 11751-11756
14. Christiansen D, Mouhtouris E, Milland J, Zingoni A, Santoni A, Sandrin MS. (2006). Recognition of a carbohydrate xenoepitope by human NKRP1A (CD161) . Xenotransplantation 13: 440-446
15. Clarke K, Lee FT, Brechbiel MW, Smyth FE, Old LJ, Scott AM (2000a) In vivo biodistribution of a humanized anti-Lewis Y monoclonal antibody (hu3S193) in MCF-7 xenografted BALB/c nude mice. Cancer Res 60: 4804-4811
16. Clarke K, Lee FT, Brechbiel MW, Smyth FE, Old LJ, Scott AM (2000b) Therapeutic efficacy of anti-Lewis (y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy. Clin Cancer Res 6: 3621-3628
17. Cooper DK, Ayares D. (2011). The immense potential of xenotransplantation in surgery. Int J Surg. doi: 10.1016/j.ijsu.2010.11.002
18. Cowan PJ, Roussel JC, d'Apice AJ. (2009). The vascular and coagulation issues in xenotransplantation. Curr Opin Organ Transplant 14: 161-167
19. Crew RJ, Ratner LE. (2010). ABO-incompatible kidney transplantation: current practice and the decade ahead. Curr Opin Organ Transplant 15: 526-530
20. DeMarco ML, Woods RJ. (2008). Structural glycobiology: a game of snakes and ladders. Glycobiology 18: 426-440
21. Dipchand AI, Pollock BarZiv SM, Manlhiot C, West LJ, VanderVliet M, McCrindle BW. (2010). Equivalent outcomes for pediatric heart transplantation recipients: ABO-blood group incompatible versus ABO-compatible. Am J Transplant 10: 389-397
22. Dokurno P, Bates PA, Band HA, Stewart LM, Lally JM, Burchell JM, Taylor-Papadimitriou J, Snary D, Sternberg MJ, Freemont PS. (1998). Crystal structure at 1.95 A resolution of the breast tumour-specific antibody SM3 complexed with its peptide epitope reveals novel hypervariable loop recognition. J Mol Biol 284: 713-728
23. Donald AS, Yates AD, Soh CP, Morgan WT, Watkins WM. (1983). A blood group Sda-active pentasaccharide isolated from Tamm-Horsfall urinary glycoprotein. Biochem Biophys Res Commun 115: 625-631
24. Ekser B, Cooper DK. (2010). Overcoming the barriers to xenotransplantation: prospects for the future. Expert Rev Clin Immunol 6: 219-230
25. Ezzelarab M, Ayares D, Cooper DK. (2005). Carbohydrates in xenotransplantation. Immunol Cell Biol 83: 396-404
26. Farrugia W, Scott AM, Ramsland PA. (2009). A possible role for metallic ions in the carbohydrate cluster recognition displayed by a Lewis Y specific antibody. PLoS One 4: e7777
27. Forte P, Pazmany L, Matter-Reissmann UB, Stussi G, Schneider MK, Seebach JD. (2001). HLA-G inhibits rolling adhesion of activated human NK cells on porcine endothelial cells. J Immunol 167: 6002-6008
28. Frank M, Schloissnig S. (2010). Bioinformatics and molecular modeling in glycobiology. Cell Mol Life Sci 67: 2749-2772
29. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shelley M, Perry JK, Shaw DE, Francis P, Shenkin PS. (2004). Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47: 1739-1749
30. Galili U, Clark MR, Shohet SB, Buehler J, Macher BA. (1987). Evolutionary relationship between the natural anti-Gal antibody and the Gal a (13) Gal epitope in primates. Proc Natl Acad Sci USA 84: 1369-1373
31. Glennie MJ, van De Winkel JG. (2003). Renaissance of cancer therapeutic antibodies. Drug Discov Today 8: 503-510
32. Good AH, Cooper DK, Malcolm AJ, Ippolito RM, Koren E, Neethling FA, Ye Y, Zuhdi N, Lamontagne LR. (1992). Identification of carbohydrate structures that bind human antiporcine antibodies: implications for discordant xenografting in humans. Transplant Proc 24: 559-562
33. Gura T. (2002). Therapeutic antibodies: magic bullets hit the target. Nature 417: 584-586
34. Hakomori S. (1999). Antigen structure and genetic basis of histo-blood groups A, B and O: their changes associated with human cancer. Biochim Biophys Acta 1473: 247-266
35. Hakomori S. (2001). Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv Exp Med Biol 491: 369-402
36. Hanai N, Nakamura K, Shitara K. (2000). Recombinant antibodies against ganglioside expressed on tumor cells. Cancer Chemother Pharmacol 46 (Suppl): S13-S17
37. Harnden I, Kiernan K, Kearns-Jonker M. (2010). The anti-nonGal xenoantibody response to a1, 3- galactosyltransferase gene knockout pig xenografts. Curr Opin Organ Transplant 15: 207-211
38. Herbertson RA, Tebbutt NC, Lee FT, MacFarlane DJ, Chappell B, Micallef N, Lee ST, Saunder T, Hopkins W, Smyth FE, Wyld DK, Bellen J, Sonnichsen DS, BrechbielMW, Murone C, Scott AM. (2009). Phase I biodistribution and pharmacokinetic study of LewisY-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers. Clin Cancer Res 15: 6709-6715
39. Higashi H, Naiki M, Matuo S, Okouchi K. (1977). Antigen of serum sickness type of heterophile antibodies in human sera: indentification as gangliosides with N-glycolylneuraminic acid. Biochem Biophys Res Commun 79: 388-395
40. Holgersson J, Gustafsson A, Breimer ME. (2005). Characteristics of protein-carbohydrate interactions as a basis for developing novel carbohydrate-based antirejection therapies. Immunol Cell Biol 83: 694-708
41. Jeffrey PD, Bajorath J, Chang CY, Yelton D, Hellstrom I, Hellstrom KE, Sheriff S. (1995). The X-ray structure of an anti-tumour antibody in complex with antigen. Nat Struct Biol 2: 466-471
42. Jones G, Willett P, Glen RC, Leach AR, Taylor R. (1997). Development and validation of a genetic algorithm for flexible docking. J Mol Biol 267: 727-748
43. Kaminski MJ, MacKenzie CR, Mooibroek MJ, Dahms TE, Hirama T, Houghton AN, Chapman PB, Evans SV (1999a) The role of homophilic binding in anti-tumor antibody R24 recognition of molecular surfaces. Demonstration of an intermolecular b-sheet between interaction between VH domains. J Biol Chem 274: 5597-5604
44. Kaminski MJ, MacKenzie CR, Mooibroek MJ, Dahms TE, Hirama T, Houghton AN, Chapman PB, Evans SV (1999b) The role of homophilic binding in anti-tumor antibody R24 recognition of molecular surfaces. Demonstration of an intermolecular beta-sheet interaction between VH domains. J Biol Chem 274: 5597-5604
45. Kearns-Jonker M, Barteneva N, Mencel R, Hussain N, Shulkin I, Xu A, Yew M, Cramer DV. (2007). Use of molecular modeling and site-directed mutagenesis to define the structural basis for the immune response to carbohydrate xenoantigens. BMC Immunol 8: 3
46. Kelly MP, Lee FT, Tahtis K, Smyth FE, Brechbiel MW, Scott AM. (2007). Radioimmunotherapywith alpha-particle emitting 213Bi-C-functionalized trans-cyclohexyl-diethylenetriaminepentaacetic acid-humanized 3S193 is enhanced by combination with paclitaxel chemotherapy. Clin Cancer Res 13: 5604s-5612s
47. Kelly MP, Lee ST, Lee FT, Smyth FE, Davis ID, Brechbiel MW, Scott AM. (2009). Therapeutic efficacy of 177Lu-CHX-A00-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy. Prostate 69: 92-104
48. Kitamura K, Stockert E, Garin-Chesa P, Welt S, Lloyd KO, Armour KL, Wallace TP, Harris WJ, Carr FJ, Old LJ. (1994). Specificity analysis of blood group Lewis-y (Le (y) ) antibodies generatedagainst synthetic and natural Le (y) determinants. Proc Natl Acad Sci USA 91: 12957-12961
49. Kobata A, Amano J. (2005). Altered glycosylation of proteins produced by malignant cells, and application for the diagnosis and immunotherapy of tumours. Immunol Cell Biol 83: 429-439
50. Krengel U, Olsson LL, Martinez C, Talavera A, Rojas G, Mier E, Angstrom J, Moreno E. (2004). Structure and molecular interactions of a unique antitumor antibody specific for N-glycolyl GM3. J Biol Chem 279: 5597-5603
51. Krug LM, Milton DT, Jungbluth AA, Chen LC, Quaia E, Pandit-Taskar N, Nagel A, Jones J, Kris MG, Finn R, Smith-Jones P, Scott AM, Old L, Divgi C. (2007). Targeting Lewis Y (Le (y) ) in small cell lung cancer with a humanized monoclonal antibody, hu3S193: a pilot trial testing two dose levels. J Thorac Oncol 2: 947-952
52. Lee FT, Rigopoulos A, Hall C, Clarke K, Cody SH, Smyth FE, Liu Z, Brechbiel MW, Hanai N, Nice EC, Catimel B, Burgess AW, Welt S, Ritter G, Old LJ, Scott AM. (2001). Specific localization, gamma camera imaging, and intracellular trafficking of radiolabelled chimeric anti-G (D3) ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenografts. Cancer Res 61: 4474-4482
53. Lefranc M-P, Pommié C, Manuel R, Giudicelli V, Foulquier E, Truong L, Thouvenin-Contet V, Lefranc G. (2003). IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains. Dev Comp Immunol 27: 55-77
54. Lin CC, Ezzelarab M, Hara H, Long C, Lin CW, Dorling A, Cooper DK. (2010). Atorvastatin or transgenic expression of TFPI inhibits coagulation initiated by anti-nonGal IgG binding to porcine aortic endothelial cells. J Thromb Haemost 8: 2001-2010
55. Lucq J, Tixier D, Guinault AM, Greffard A, Loisance D, Pilatte Y. (2000). The target antigens of naturally occurring human anti-b-galactose IgG are cryptic on porcine aortic endothelial cells. Xenotransplantation 7: 3-13
56. Milland J, Christiansen D, Sandrin MS. (2005). a1, 3-Galactosyltransferase knockout pigs are available for xenotransplantation: are glycosyltransferases still relevant?. Immunol Cell Biol 83: 687-693
57. Milland J, Yuriev E, Xing PX, McKenzie IF, Ramsland PA, Sandrin MS. (2007). Carbohydrate residues downstream of the terminal Gala (1, 3) Gal epitope modulate the specificity of xenoreactive antibodies. Immunol Cell Biol 85: 623-632
58. Miwa Y, Kobayashi T, Nagasaka T, Liu D, Yu M, Yokoyama I, Suzuki A, Nakao A. (2004). Are Nglycolylneuraminic acid (Hanganutziu-Deicher) antigens important in pig-to-human xenotransplantation?. Xenotransplantation 11: 247-253
59. Modak S, Cheung NK. (2010). Neuroblastoma: therapeutic strategies for a clinical enigma. Cancer Treat Rev 36: 307-317
60. Nottle MB, Vassiliev I, O'Connel PJ, d'Apice AJ, Cowan PJ. (2010). On the need for porcine embryonic stem cells to produce Gal KO pigs expressing multiple transgenes to advance xenotransplantation research. Xenotransplantation 17: 411-412
61. Pichla SL, Murali R, Burnett RM. (1997). The crystal structure of a Fab fragment to the melanomaassociated GD2 ganglioside. J Struct Biol 119: 6-16
62. Ramsland PA, Farrugia W, Yuriev E, Edmundson AB, Sandrin MS. (2003). Evidence for structurally conserved recognition of the major carbohydrate xenoantigen by natural antibodies. Cell Mol Biol (Noisy-le-Grand) 49: 307-317
63. Ramsland PA, Farrugia W, Bradford T, Hogarth PM, Scott AM. (2004). Structural convergence of antibody binding of carbohydrate determinants in Lewis Y tumor antigens. J Mol Biol 340: 809-818
64. Ramsland P. (2005). Blood brothers: carbohydrates in xenotransplantation and cancer immunotherapy. Immunol Cell Biol 83: 315-317
65. Reis CA, Osorio H, Silva L, Gomes C, David L. (2010). Alterations in glycosylation as biomarkers for cancer detection. J Clin Pathol 63: 322-329
66. Reynolds M, Fuchs A, Lindhorst TK, Perez S. (2008). The hydration features of carbohydrate determinants of Lewis antigens. Mol Simul 34: 447-460
67. Rood PP, Hara H, Ezzelarab M, Busch J, Zhu X, Ibrahim Z, Ball S, Ayares D, Awwad M, Cooper DK. (2005). Preformed antibodies to a1, 3-galactosyltransferase gene-knockout (GT-KO) pig cells in humans, baboons, and monkeys: implications for xenotransplantation. Transplant Proc 37: 3514-3515
68. Rood PP, Tai HC, Hara H, Long C, Ezzelarab M, Lin YJ, van Der Windt DJ, Busch J, Ayares D, Ijzermans JN, Wolf RF, Manji R, Bailey L, Cooper DK. (2007). Late onset of development of natural anti-nonGal antibodies in infant humans and baboons: implications for xenotransplantation in infants. Transpl Int 20: 1050-1058
69. Sakamoto J, Furukawa K, Cordon-Cardo C, Yin BW, Rettig WJ, Oettgen HF, Old LJ, Lloyd KO. (1986). Expression of Lewisa, Lewisb, X, and Y blood group antigens in human colonic tumors and normal tissue and in human tumor-derived cell lines. Cancer Res 46: 1553-1561
70. Saleh MN, Sugarman S, Murray J, Ostroff JB, Healey D, Jones D, Daniel CR, LeBherz D, Brewer H, Onetto N, LoBuglio AF. (2000). Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with Lewis Y-expressing epithelial tumors. J Clin Oncol 18: 2282-2292
71. Sandrin MS, Vaughan HA, Dabkowski PL, McKenzie IF. (1993). Anti-pig IgM antibodies in human serum react predominantly with Gal (a1-3) Gal epitopes. Proc Natl Acad Sci USA 90: 11391-11395
72. Schlimok G, Pantel K, Loibner H, Fackler-Schwalbe I, Riethmuller G. (1995). Reduction of metastatic carcinoma cells in bone marrow by intravenously administered monoclonal antibody: towards a novel surrogate test to monitor adjuvant therapies of solid tumours. Eur J Cancer 31A: 1799-1803
73. Schrödinger LLC (2010a) Prime, version 2.2. New York
74. Schrödinger LLC (2010b) The PyMOL molecular graphics system, Version 1.3r1, New York
75. Scott AM, Renner C. (2001). Tumour antigens recognized by antibodies. In: Encyclopedia of life sciences. Wiley. doi: 10.1038/npg.els.0001433, Chichester, UK
76. Scott AM, Geleick D, Rubira M, Clarke K, Nice EC, Smyth FE, Stockert E, Richards EC, Carr FJ, Harris WJ, Armour KL, Rood J, Kypridis A, Kronina V, Murphy R, Lee FT, Liu Z, Kitamura K, Ritter G, Laughton K, Hoffman E, Burgess AW, Old LJ. (2000). Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors. Cancer Res 60: 3254-3261
77. Scott AM, Lee FT, Hopkins W, Cebon JS, Wheatley JM, Liu Z, Smyth FE, Murone C, Sturrock S, MacGregor D, Hanai N, Inoue K, Yamasaki M, Brechbiel MW, Davis ID, Murphy R, Hannah A, Lim-Joon M, Chan T, Chong G, Ritter G, Hoffman EW, Burgess AW, Old LJ. (2001). Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: results of a phase I trial. J Clin Oncol 19: 3976-3987
78. Scott AM, Liu Z, Murone C, Johns TG, MacGregor D, Smyth FE, Lee FT, Cebon J, Davis ID, Hopkins W, Mountain AJ, Rigopoulos A, Hanai N, Old LJ. (2005). Immunological effects of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma. Cancer Immun 5: 3
79. Scott AM, Tebbutt N, Lee FT, Cavicchiolo T, Liu Z, Gill S, Poon AM, Hopkins W, Smyth FE, Murone C, MacGregor D, Papenfuss AT, Chappell B, Saunder TH, Brechbiel MW, Davis ID, Murphy R, Chong G, Hoffman EW, Old LJ. (2007). A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen. Clin Cancer Res 13: 3286-3292
80. Seeberger PH. (2008). Automated carbohydrate synthesis as platform to address fundamental aspects of glycobiology - current status and future challenges. Carbohydr Res 343: 1889-1896
81. Sheriff S, Chang CY, Jeffrey PD, Bajorath J. (1996). X-ray structure of the uncomplexed anti-tumor antibody BR96 and comparison with its antigen-bound form. J Mol Biol 259: 938-946
82. Shitara K, Kuwana Y, Nakamura K, Tokutake Y, Ohta S, Miyaji H, Hasegawa M, Hanai N. (1993). A mouse/human chimeric anti- (ganglioside GD3) antibody with enhanced antitumor activities. Cancer Immunol Immunother 36: 373-380
83. Shusterman S, London WB, Gillies SD, Hank JA, Voss SD, Seeger RC, Reynolds CP, Kimball J, Albertini MR, Wagner B, Gan J, Eickhoff J, DeSantes KB, Cohn SL, Hecht T, Gadbaw B, Reisfeld RA, Maris JM, Sondel PM. (2010). Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children?s Oncology Group (COG) phase II study. J Clin Oncol 28: 4969-4975
84. Slovin SF, Keding SJ, Ragupathi G. (2005). Carbohydrate vaccines as immunotherapy for cancer. Immunol Cell Biol 83: 418-428
85. Song KH, Kang YJ, Jin UH, Park YI, Kim SM, Seong HH, Hwang S, Yang BS, Im GS, Min KS, Kim JH, Chang YC, Kim NH, Lee YC, Kim CH. (2010). Cloning and functional characterization of pig CMP-N-acetylneuraminic acid hydroxylase for the synthesis of N-glycolylneuraminic acid as the xenoantigenic determinant in pig-human xenotransplantation. Biochem J 427: 179-188
86. Talavera A, Eriksson A, Okvist M, Lopez-Requena A, Fernandez-Marrero Y, Perez R, Moreno E, Krengel U. (2009). Crystal structure of an anti-ganglioside antibody, and modelling of the functional mimicry of its NeuGc-GM3 antigen by an anti-idiotypic antibody. Mol Immunol 46: 3466-3475
87. Tangvoranuntakul P, Gagneux P, Diaz S, Bardor M, Varki N, Varki A, Muchmore E. (2003). Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc Natl Acad Sci USA 100: 12045-12050
88. Taylor ME, Drickamer K. (2009). Structural insights into what glycan arrays tell us about how glycan-binding proteins interact with their ligands. Glycobiology 19: 1155-1162
89. Tolcher AW, Sugarman S, Gelmon KA, Cohen R, Saleh M, Isaacs C, Young L, Healey D, Onetto N, Slichenmyer W. (1999). Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J Clin Oncol 17: 478-484
90. Tseng YL, Moran K, Dor FJ, Sanderson TM, Li W, Lancos CJ, Schuurman HJ, Sachs DH, Cooper DK. (2006). Elicited antibodies in baboons exposed to tissues from a1, 3-galactosyltransferase gene-knockout pigs. Transplantation 81: 1058-1062
91. van Roon AM, Pannu NS, De Vrind JP, van Der Marel GA, van Boom JH, Hokke CH, Deelder AM, Abrahams JP. (2004). Structure of an anti-Lewis X Fab fragment in complex with its Lewis X antigen. Structure 12: 1227-1236
92. Vázquez AM, Alfonso M, Lanne B, Karlsson K-A, Carr A, Barroso O, Fernández LE, Rengifo E, Lanio ME, Alvarez C, Zeuthen J, Pérez R. (1995). Generation of a murine monoclonal antibody specific for N-glycolylneuraminic acid-containing gangliosides that also recognizes sulfated glycolipids. Hybridoma 14: 551-556
93. Weiss EH, Lilienfeld BG, Muller S, Muller E, Herbach N, Kessler B, Wanke R, Schwinzer R, Seebach JD, Wolf E, Brem G. (2009). HLA-E/human b2-microglobulin transgenic pigs: protection against xenogeneic human anti-pig natural killer cell cytotoxicity. Transplantation 87: 35-43
94. Woods RJ, Tessier MB. (2010). Computational glycoscience: characterizing the spatial and temporal properties of glycans and glycan-protein complexes. Curr Opin Struct Biol 20: 575-583
95. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM. (2010). Anti-GD2 antibody with GMCSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 363: 1324-1334
96. Yuriev E, Farrugia W, Scott AM, Ramsland PA. (2005). Three-dimensional structures of carbohydrate determinants of Lewis system antigens: implications for effective antibody targeting of cancer. Immunol Cell Biol 83: 709-717
97. Yuriev E, Sandrin MS, Ramsland PA. (2008). Antibody-ligand docking: insights into peptidecarbohydrate mimicry. Mol Simul 34: 461-468
98. Yuriev E, Agostino M, Farrugia W, Christiansen D, Sandrin MS, Ramsland PA. (2009). Structural biology of carbohydrate xenoantigens. Expert Opin Biol Ther 9: 1017-1029
99. Yuriev E, Agostino M, Ramsland PA. (2011). Challenges and advances in computational docking: 2009 in review. J Mol Recognit 24: 149-164
100. Zhu A, Hurst R. (2002). Anti-N-glycolylneuraminic acid antibodies identified in healthy human serum. Xenotransplantation 9: 376-381